High throughput phenotyping and drug discovery using the TumorGraft3D co-culture platform and flow cytometry - AACR 2025

Evaluating the limitations of current stabilization and cryopreservation methods for flow cytometric analysis - CYTO 2025

Considerations for Global Harmonization and Quality Assessments using spectral flow cytometers - CYTO 2025

Development and Validation of a 29-Color Immunophenotyping panel for the 3-laser Cytek Northern Lights - CYTO 2024

Evaluation of PBMC Isolation Methods and the Impact of Cryopreservation  - CYTO 2024

Immunophenotyping via High Complexity Flow Cytometry in Acute Myeloid Leukemia - AACR 2024

Development of a Flow Cytometric Receptor Occupancy Assay for Clinical Analysis of Immune Checkpoint Inhibitor Therapeutics - SITC 2023

Targeted Immunotherapies in Multiple Myeloma: Focus on Flow Cytometry Markers and Therapeutic Implications - AACR 2025

Primary, Fully Characterized Autologous AML System allows the Correlation of T Cell Activation with Leukemia Cell Survival upon Io Treatment in a Novel Autologous System - SITC 2024

Systematic Analysis of Gene Mutations and Therapeutic Efficacy via Ex vivo Hematological VitroScreen Platform - AACR 2024

Unveiling the Correlation between gemtuzumab-ozogamicin Efficacy and CD33+ Expression in AML Primary Samples Using the Novel AML VitroScreen - AACR 2024

Ex Vivo Modeling of Multiple Myeloma: A Novel Drug Sensitivity Screening Platform - AACR 2023

In Vitro Drug Sensitivity Screening Platform for Chronic Lymphocytic Leukemia (CLL) Patient Samples - AACR 2021

In Vitro and In Vivo Model for Evaluation of Novel Therapeutic Agents in Patient-derived Lymphoblastic Leukemia (B-ALL) - AACR 2021

2D Ex Vivo Patient-Derived Acute Myeloid Leukemia Platform for Evaluation of Novel Molecular Targeted Therapeutic Agents - AACR 2020

Development of an HLA-matched humanized immune system mouse model with primary AML patient samples for immunotherapy testing - AACR 2025

Development of a Non-small cell lung cancer PDX model in a myeloid-boosted humanized host highlights an M2 polarization phenotype within the myeloid compartment - SITC 2023

A Novel Gene Signature predicts immune infiltration phenotypes in humanized Patient-Derived Xenograft Models - SITC 2023

Natural Killer (NK) Human Immune System (HIS) ImmunoGraft^® Platform to Evaluate the Pharmacodynamics of Immuno-Oncology Therapeutics - AACR 2020

Unique Immunodeficient Murine Host Strains Impact Expansion and Engraftment of T Cells in PBMC Humanized Mice - NYAS 2019

Development of a Peripheral Blood Mononuclear Cells (PBMC) ImmunoGraft^® Platform to Evaluate of the Pharmacodynamics of Immuno Oncology Therapeutics - SITC 2019

Computational deconvolution identifies a Th2-enriched immune-inflammatory signature in invasive breast carcinoma - SITC 2023

A Pharmaco-Pheno-Multiomic Integration Analysis of Pancreatic Cancer: A Highly Predictive Biomarker Model of Biomarkers of Gemcitabine/Abraxane Sensitivity and Resistance - AACR 2023

Multiomic Approaches to Illuminate Molecular Drivers of Breast Cancer Metastasis to the Liver - AACR 2023

A Pharmaco-Pheno-Multiomic Integration Analysis of Primary Acute Myeloid Leukemia Reveals Biomarkers of Cytarabine Resistance - AACR 2022

Pharmaco-Pheno-Multiomic Integration Builds A Biomarker Network of Olaparib Resistance in Ovarian Cancer - AACR 2022

Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for evaluating cMET-targeted therapies - AACR 2025

Investigating the efficacy of 177-Lu therapeutics in a series of Castrate Resistant Prostate Cancer PDX Models - AACR 2025

Multi-omics and histological assessment to identify patient-derived xenograft models of invasive lobular carcinoma - AACR 2025

Establishment of an orthotopic intracranial luciferase labelled patient-derived xenograft of glioblastoma in immunocompromised mice model - AACR 2025

Leveraging the tumor microenvironment (TME) atlas to identify the best PDX model for pre-clinical testing of TME targeting agents - AACR 2025

An integrated preclinical platform for Antibody-Drug Conjugate development - AACR 2025

An Integrated Platform for Antibody-Drug Conjugate Discovery and Development - Tumor Models San Francisco 2025

Mutational signatures in PDXs for improved understanding of drug response and companion biomarkers identification - AACR 2024

A Novel Gene Signature predicting fibroblast composition in the TME allows for an improved selection of PDX models for preclinical studies - AACR 2024

Raptamer-Drug Conjugates as Molecularly Targets Cancer Therapeutics - AACR 2023

Combining Multiomics and Histological Assessment to Identify Patient-derived Xenograft Models of Invasive Lobular Carcinoma - San Antonio Breast Cancer Symposium 2022

Advancing CAR-Ts and anti-immunosuppressive therapy development: Immunosuppressive TME 3D co-culture platform grounded on a fully characterized PDX tumor Bank - AACR 2025

Comparative analysis of mutational signatures in TumorGraft PDX bank and TCGA dataset to improve patient tumor modeling - AACR 2025

Building 3D ex vivo models as a powerful platform for anti-cancer drug and biomarker discovery - AACR 2025

HER2-positive patient-derived xenograft organoids (PDXOs) as a novel preclinical tool to evaluate new therapies against HER2-driven cancers - AACR 2025

High-throughput screening of clinically relevant patient-derived 3D cultures to inform on the efficacy of Antibody Drug Conjugate Payloads in 10 distinct cancer indications - AACR 2025

Predicting clinical checkpoint inhibitor responses with TumorGraft3D PBMC co-culture - AACR 2025

Primary, fully characterized autologous AML system allows the correlation of T cell activation with leukemia cell survival upon IO treatment in a novel autologous system - SITC 2024

Bioluminescent 3D Tumors with Immune Cell Co-culture for High Throughput Screening (HTS) - AACR 2024

Tumor-on-Chip Co-culture System: An Innovative Tool in Personalized Medicine to Investigate Cancer Progression - AACR 2024

A Novel 3D Co-Culture Platform for Patient-Specific Immune-Oncology Treatment - AACR 2024

An Innovative PDX and Patient-derived 3D Platform for Improved Translatability of New Medical Entities - AACR 2024

A Novel TumorGraft3D immune co-culture platform for high throughput immune-oncology screening - SITC 2023

Establishment of Tumor-on-Chip system to study the role of tumor microenvironment on cancer progression in a patient-specific manner - SITC 2023

Identification of synergistic combination of molecular targeted agents and chemotherapy using TumorGraft3D and Lumin platform - Tumor Models Boston 2023

Unique 3D Organoids Autologous TIL Co-Culture Platform Enables High Throughput Immune-Oncology Drug Response Studies - AACR 2021

3D Co-Culture Platform Reveals Insights into Patient Autologous Immune Cell-Tumor Interaction and Immune Modulation In Vitro - SITC 2021

Development of a 3D Organoid Autologous TIL Co-Culture Platform for High Throughput Immuno-Oncology Studies - SITC 2020